Preferred Label : Izalontamab Brengitecan;
NCIt synonyms : Dual Target ADC BL-B01D1; ADC BL-B01D1; Anti-EGFR/HER3 ADC BL-B01D1; Dual Antibody ADC BL-B01D1; Anti-EGFR/anti-HER3 ADC BL-B01D1;
NCIt definition : A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody
directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and
the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B
cleavable linker, to the camptothecin derivative and topoisomerase 1 inhibitor Ed-04,
with potential antineoplastic activity. Upon administration of izalontamab brengitecan,
the bispecific antibody moiety simultaneously targets and binds to EGFR and HER3 expressed
on cancer cells. Upon binding and internalization, Ed-04 is released and inhibits
DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in
cell cycle arrest and apoptosis in tumor cells expressing EGFR and/or HER3. EGFR and
HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles
in tumor cell proliferation. Simultaneously targeting both EGFR and HER3 may enhance
the anti-tumor activity of izalontamab brengitecan.;
UNII : UC2FX6YY3P;
CAS number : 2760528-47-8;
Molecule name : BL-B01D1; BL B01D1;
NCI Metathesaurus CUI : CL1922205;
Origin ID : C203048;
UMLS CUI : C5908939;
Semantic type(s)
- concept_is_in_subset
- has_target
